Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

TESARO Inc (NASDAQ:TSRO)

53.36
Delayed Data
As of Aug 28
 +3.00 / +5.96%
Today’s Change
23.00
Today|||52-Week Range
66.95
+43.48%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.1B

Company Description

TESARO, Inc. is an oncology-focused biopharmaceutical company. It is dedicated to improving the lives of cancer patients. The company's product portfolio currently consists of three oncology-related product candidates: Rolapitant, Niraparib and TSR-011. TESARO was founded by Leon Moulder, Jr., Mary Lynne Hedley and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA.

Contact Information

TESARO, Inc.
1000 Winter Street
Waltham Massachusetts 02451
P:(339) 970-0900
Investor Relations:
(781) 325-1116

Employees

Shareholders

Mutual fund holders51.23%
Individual stakeholders36.16%
Other institutional30.71%

Top Executives

Leon O. MoulderChief Executive Officer & Director
Mary Lynne HedleyPresident, Chief Operating Officer & Director
Timothy R. PearsonChief Financial Officer & Executive Vice President
Robert E. MartellChief Medical Officer
Lori Rudolph-OwenVP-Portfolio Management, Research & Development